Sally Kay

Of Counsel
Full contact info

The biggest reward in my job is helping first-time founders transform into successful entrepreneurs.

Passions

Warriors Basketball

Live Music

All Things UCLA

Experience

AN2 Therapeutics – $79 Million IPO

March 25, 2022

Cooley advised AN2 Therapeutics on its $79 million initial public offering of 4,600,000 shares of common stock at a price to the public of $15.00 per share. AN2 is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Partner Josh Seidenfeld, associate Anitha Anne and Sally Kay of counsel led the Cooley team.

Related contacts

Josh Seidenfeld
Partner, Palo Alto
Anitha Anne
Associate, San Francisco
Sally Kay
Of Counsel, Palo Alto
Kristina Krasnikova
Associate, Palo Alto
Barbara Mirza
Partner, Santa Monica
Alexander Ellebracht
Associate, Palo Alto

Related Practices & Industries

Portola Agrees to Sell to Alexion for $1.41 Billion

May 6, 2020

Cooley advised Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders, on its agreement to sell to Alexion Pharmaceuticals for $18 per share in cash – a value of $1.41 billion. Jamie Leigh, Ian Nussbaum, Kenneth Guernsey, Robert Jones and Sally Kay led the Cooley team advising Portola on the transaction, which is expected to close in Q3. 

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Kenneth Guernsey
Senior Counsel , San Francisco
Robert L. Jones
Partner, Palo Alto
Sally Kay
Of Counsel, Palo Alto
Howard Morse
Partner, Washington, DC
Barbara Mirza
Partner, Santa Monica
Lila Hope
Partner, Palo Alto
Alexander Israel
Partner in Charge – Brussels, Brussels
Wendy Brenner
Partner, Palo Alto
Julia R. Brinton
Associate, Washington, DC
Austin Holt
Partner, Santa Monica
Jan Lang
Associate, Brussels
Timothy Shapiro
Partner, Palo Alto
Matthew D. Silverman
Special Counsel, Santa Monica

Related Practices & Industries

ProteinSimple $300 Million Sale to Techne Corporation

June 20, 2014

Palo Alto, Calif. – Cooley is advising ProteinSimple on its sale to Techne (d/b/a Bio-Techne) for $300 million. ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Techne is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities.

The transaction is subject to the satisfaction of customary closing conditions and will be financed through a combination of cash on hand and a new revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.

Related contacts

Mark Weeks
Partner, Palo Alto
Sally Kay
Of Counsel, Palo Alto
Jamie Leigh
Partner, San Francisco
Sepideh Mousakhani
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Todd Gluth
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC

Related Practices & Industries

Portola Pharmaceuticals $140 Million IPO

May 29, 2013

Palo Alto, Calif. – Cooley advised Portola Pharmaceuticals on its $140 million initial public offering. Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. It now trades on the Nasdaq Global Stock Market under the symbol "PTLA.

Related contacts

Kenneth Guernsey
Senior Counsel , San Francisco
Sally Kay
Of Counsel, Palo Alto
Lila Hope
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC

Admissions and credentials

California

Memberships and affiliations

American Bar Association (ABA)

State Bar of California

Cooley GO

Start and build your business with our one-stop spot for tips, documents and insights.